NovoCure Valuation
Is NVCR N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NVCR N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NVCR N's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NVCR N's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NVCR N?
Key metric: As NVCR N is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is NVCR N's PS Ratio? | |
|---|---|
| PS Ratio | 3.2x |
| Sales | US$503.98m |
| Market Cap | US$1.60b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.5x |
| Enterprise Value/EBITDA | -5.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NVCR N's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.9x | ||
301363 MeHow Innovative | 8.5x | 25.4% | CN¥12.3b |
688139 Qingdao Haier BiomedicalLtd | 4.6x | 24.0% | CN¥10.4b |
IART Integra LifeSciences Holdings | 1.2x | 5.8% | US$1.9b |
600587 Shinva Medical InstrumentLtd | 1.1x | 12.0% | CN¥10.6b |
NVCR N NovoCure | 3.2x | 7.1% | Mex$1.6b |
Price-To-Sales vs Peers: NVCR N is expensive based on its Price-To-Sales Ratio (3.2x) compared to the peer average (3.1x).
Price to Sales Ratio vs Industry
How does NVCR N's PS Ratio compare vs other companies in the Global Medical Equipment Industry?
| 127 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 127 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: NVCR N is good value based on its Price-To-Sales Ratio (3.2x) compared to the Global Medical Equipment industry average (3.6x).
Price to Sales Ratio vs Fair Ratio
What is NVCR N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NVCR N's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.